Literature DB >> 3826125

Hemolytic anemia following intravenous gamma globulin administration.

A G Brox, D Cournoyer, M Sternbach, G Spurll.   

Abstract

A young homosexual man with immune thrombocytopenia recently had transient intravascular hemolysis during intravenous gamma globulin treatment. The hemolysis, manifested by a sharp decrease in hemoglobin and by a direct Coombs' test with a positive result, was mediated by anti-A antibody present in the gamma globulin preparation. In view of the increasing use of intravenous gamma globulin in the treatment of patients with immune cytopenia, this problem may result in crossmatching difficulties and should be recognized as a potential complication of therapy.

Entities:  

Mesh:

Year:  1987        PMID: 3826125     DOI: 10.1016/0002-9343(87)90112-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 4.  Side-effects of intravenous immune globulins.

Authors:  C Duhem; M A Dicato; F Ries
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

5.  Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

Authors:  Joseph Kahwaji; Eva Barker; Sam Pepkowitz; Ellen Klapper; Rafael Villicana; Alice Peng; Robert Chang; Stanley C Jordan; Ashley A Vo
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

6.  Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.

Authors:  David A Loeffler; Lynnae M Smith; Andrea C Klaver; Heather A Brzezinski; Essie I Morrison; Mary P Coffey; Barbara A Steficek; Susan S Cook
Journal:  Comp Med       Date:  2012-02       Impact factor: 0.982

Review 7.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 8.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

Review 9.  Intravenous immunoglobulin and Alzheimer's disease: what now?

Authors:  David A Loeffler
Journal:  J Neuroinflammation       Date:  2013-06-05       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.